driving school

Biovica International AB is a biotechnology company based in Uppsala, Sweden, focused on developing and commercializing blood-based biomarker assays to enhance the monitoring of cancer therapies and predict patient outcomes. Primarily targeting breast cancer, Biovica's flagship product, DiviTum, measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures to evaluate therapy effectiveness. DiviTum has shown success in clinical trials for early assessment of treatment response and is designed to facilitate optimal patient care from the outset. The company collaborates with leading cancer institutes and pharmaceutical firms to support the launch of next-generation therapies. Biovica is ISO 13485 certified for Quality Management Systems, and DiviTum is CE-labeled and MPA-registered, ensuring compliance with regulatory standards.